Alnylam Pharmaceuticals | Gastos De Venta Y Administración



Selling And Administration Expenses Cambio Fecha
Acadia Pharmaceuticals USD 130.08M 3.21M 2024-12
Agios Pharmaceuticals USD 41.53M 10.17M 2025-03
Alnylam Pharmaceuticals USD 239.95M 55.39M 2025-03
Amgen USD 1.69B 191M 2025-03
Arrowhead Research USD 30.2M 1.91M 2024-12
BioMarin Pharmaceutical USD 206.12M 50.65M 2025-03
Incyte USD 325.69M 1.02M 2025-03
Ionis Pharmaceuticals USD 76M 12.08M 2025-03
Moderna USD 212M 139M 2025-03
Neurocrine Biosciences USD 287.8M 53.5M 2024-12
Novartis USD 3.5B 368M 2024-12
PTC Therapeutics USD 84.68M 11.23M 2024-12
Regeneron Pharmaceuticals USD 633M 159.2M 2025-03
Sanofi EUR 1.24B 1.44B 2024-12
Sarepta Therapeutics USD 163.87M 35.67M 2024-12
Takeda JPY 270.59B 2.31B 2024-12
Tectonic Therapeutic USD 4.84M 469K 2024-12
Ultragenyx Pharmaceutical USD 82.49M 2.14M 2024-12
Vertex Pharmaceuticals USD 377.6M 5.8M 2024-12
Xencor USD 14.92M 148K 2024-12



Alnylam Pharmaceuticals Gastos De Venta Y Administración - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - May 2025.